TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06543459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
Study: NCT02497222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT05155124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + trifluridin tipiracil
Description: Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
Study: NCT06445699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
Study: NCT05756920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL301
Description: SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
Study: NCT05673824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEGFR-TKIs
Description: Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study: NCT05742412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video streaming (smartphone camera)
Description: Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
Study: NCT06052085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Program
Description: Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
Study: NCT05742412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telephone (telephone microphone)
Description: Usual care: Audio-based-only communication using telephone during emergency medical dispatch
Study: NCT05316480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 200mg/week
Study: NCT04934449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Using occlusal splints during sleep for 2 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Using occlusal splints during sleep for 2 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Using occlusal splints during sleep for 2 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Description: Using occlusal splints during sleep for 2 months
Study: NCT05929638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lavender oil
Description: The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
Study: NCT05789693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity changes
Description: Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
Study: NCT06436040

Intervention type: OTHER
Intervention: Pathological response assessment
Description: The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.

Intervention type: OTHER
Intervention: Pathological response assessment
Description: The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
Study: NCT04551833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Tramadol versus Dexamethasone as adjuvant to Levobupvacain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Tramadol versus Dexamethasone as adjuvant to Levobupvacain
Study: NCT02014207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary treatment
Study: NCT05220189

Intervention type: DIAGNOSTIC_TEST
Intervention: EarlyTect® Bladder Cancer test
Description: A highly accurate and sensitive real-time PCR employing Linear Target Enrichment and Quantitative Methylation-Specific PCR (LTE-qMSP) for measuring PENK methylation in urine DNA to detect bladder cancer in hematuria patients.
Study: NCT06088056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination use of SRT with T-DXd
Description: Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg
Study: NCT05379816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5% DW perineural injection
Description: 5% DW perineural injection to intercostal nerve
Study: NCT03180463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)
Description: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: core decompression
Description: The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
Study: NCT06554561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
Study: NCT04963075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multisensory rehabilitation paradigm
Description: In initial (training) sessions, subjects will be exposed (and respond) to spatiotemporally congruent pairs of visual-auditory stimuli presented within their blinded field, with occasional probes of unisensory visual stimuli on both sides of space. Once recovery of visual responsiveness in the contralesional field is observed, sessions will alternate between training/testing and testing only sessions in which performance on the visual battery will be re-assessed.
Study: NCT06164691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Participants undergoing this intervention will be exposed to blue (442nm) light.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber light
Description: Participants undergoing this intervention will be exposed to amber (617nm) light.
Study: NCT05410132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-delivered Mindfulness Based Training (iMBT)
Description: The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice.
Study: NCT04973930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Time-limited, affect-focused, empirically supported psychotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine HCl ER
Description: FDA-approved antidepressant medications
Study: NCT05056883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-237 0.3-0.4mg/kg (once daily)
Description: Ivermectin 3mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.3-0.4mg/kg (once daily)
Description: Placebo 3mg tablet
Study: NCT04672486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POD Adventures
Description: Participants in the intervention arm will receive information about local services/national helplines and a brief problem-solving intervention that is delivered through a smartphone app with telephone guidance from a lay counsellor. The intervention is grounded in stress-coping theory, with a technical focus on practical problem solving. The emphasis on problem solving reflects the primacy of psychosocial stressors in adolescent help-seeking. Moreover, problem-solving is among the most commonly used practice elements in evidence-based psychological interventions for children and adolescents globally.~The content of the app comprises two sections: 'Adventures' which teaches problem-solving concepts and methods through contextually-appropriate games; and 'My POD' which scaffolds the student through the application of step-by-step problem-solving procedures to their own prioritized problems.
Study: NCT05903950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air cleaners with HEPA filter
Description: PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Air cleaners without HEPA filter
Description: Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.
Study: NCT05459766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery
Description: Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be educated about the postoperative rehabilitation program
Study: NCT05999149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Chemotherapy and Famitinib
Description: camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab Plus Chemotherapy
Description: Camrelizumab Plus Chemotherapy
Study: NCT05800834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing.
Study: NCT06164691

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient White Light
Description: This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
Study: NCT06080763

Intervention type: PROCEDURE
Intervention: Physical Therapy Management
Description: Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.

Intervention type: PROCEDURE
Intervention: Physical Therapy Management
Description: Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
Study: NCT06377280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Mini
Description: CE-marked Navina Mini, released on the market May 2023
Study: NCT05156437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
Description: Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Description: Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Description: Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Study: NCT04807166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Anlotinib
Description: Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Carboplatin/Paclitaxel
Description: Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
Study: NCT05800834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hcl 2% Jelly
Description: The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
Study: NCT05388227

Intervention type: OTHER
Intervention: Pole Walking
Description: Group training sessions will be offered at the participating independent living/retirement communities. Training sessions will be held either indoors or outdoors, 2-3 times a week, for 20-60 min/session, over 12 weeks.
Study: NCT04998916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the mPFC
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
Study: NCT05077540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
Study: NCT06333002

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.
Study: NCT05300893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No night splint
Description: Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
Study: NCT00051090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: Administered orally at a daily dosage of 600 mg for a period of 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Administered orally at a total daily dosage of 300 mg for Weeks 24-48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Administered orally at a daily dose of 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Didanosine
Description: Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
Study: NCT06445699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel dressing
Description: Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogel dressing
Description: Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.
Study: NCT05741892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fracture reposition with 3D printed patient specific repositions guides
Description: Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
Study: NCT02859831

Intervention type: OTHER
Intervention: water samples

Intervention type: OTHER
Intervention: water samples
Study: NCT04037098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium lactate.
Description: 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets orally every 12 hours of on inert placebo for three months
Study: NCT05321017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEP Operant Up-conditioning of the Wrist Extensor
Description: This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
Study: NCT05811754

Intervention type: OTHER
Intervention: Data collection
Description: This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum.

Intervention type: OTHER
Intervention: Data collection
Description: This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum.